Novo Nordisk: Wegovy Pill Records Can’t Offset the CagriSema Setback

Despite strong Wegovy pill uptake and Medicare boost, CagriSema trails Lilly's Zepbound; focus shifts to Zenagamtide as stock languishes.

The Danish pharmaceutical giant is living a tale of two realities. Its stock clawed back 2.16 percent to €37.37 on Wednesday, yet the gain does little to mask a punishing year that has left the shares down more than 16 percent in Europe and roughly 22 percent in New York. Behind the price action lies a widening gap between stellar commercial execution and a pipeline that just stumbled in the high-stakes obesity market.

Five months after the launch of its oral Wegovy pill in the United States, Novo Nordisk has filled three million prescriptions — one pack every five seconds. Over 80 percent of buyers are new to GLP-1 therapies, suggesting the tablet format is pulling in a fresh cohort of patients who had shunned injections. A further tailwind arrives on 1 July 2026, when the Medicare GLP-1 Bridge program caps out-of-pocket costs at $50 a month for eligible seniors, covering Wegovy and rival drugs alike. The company will begin an international rollout of the pill in the second half of 2026, starting with the United Arab Emirates.

But the commercial fireworks have been dimmed by a clinical disappointment. In the REDEFINE study, Novo Nordisk’s combination therapy CagriSema delivered a 23 percent weight loss after 84 weeks — respectable by most measures, yet eclipsed by Eli Lilly’s Zepbound, which shed 25.5 percent over the same period. The miss is a blow in the race for the obesity crown. CagriSema did fare better in diabetes, however. The REIMAGINE 2 and REIMAGINE 3 trials showed meaningful improvements in blood sugar control and, when added to insulin, weight reductions of up to 12 percent. Novo Nordisk still sees the drug as a potential standard of care for type-2 diabetics.

With CagriSema’s obesity ambitions dented, attention is shifting to a younger candidate, Zenagamtide. In a phase 2 study involving 262 patients, the highest dose shaved off 14.6 percent of body weight after 36 weeks, and critically, the weight-loss curve had not yet plateaued. That suggests room for further gains in longer studies. But investors will have to wait: pivotal phase 3 trials for Zenagamtide are not expected to begin until the end of 2026, with data arriving roughly two years later.

Meanwhile, the competitive landscape is tightening fast. Eli Lilly launched its own daily GLP-1 pill, Foundayo, in April 2026, and AstraZeneca is advancing an oral candidate into phase 3 after positive phase 2b results. To accelerate its own pipeline, Novo Nordisk has turned to artificial intelligence. Since April, it has been working with OpenAI to automate data collection and run virtual clinical trials, aiming to shorten development timelines.

As the stock languishes nearly 47 percent below its 52-week high, management has leaned on a 15-billion-Danish-krone share buyback program, of which roughly five billion kroner has already been deployed. Near-term investor sentiment will largely hinge on how quickly the Wegovy pill can gain traction outside the U.S. — and whether Zenagamtide can eventually fill the gap left by CagriSema in the obesity arena.